trending Market Intelligence /marketintelligence/en/news-insights/trending/Y8C2ab4g8M2mvjrDUNooYA2 content esgSubNav
In This List

Summit Therapeutics closes $25M placement of American depositary shares

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints

Blog

Shore Capital is Now Available in S&P Global’s Aftermarket Research Collection


Summit Therapeutics closes $25M placement of American depositary shares

Summit Therapeutics PLC completed a private placement of 15,625,000 American depositary shares at $1.60 apiece to raise $25 million.

The ADS in the offering represented 78,125,000 new ordinary shares of Summit Therapeutics.

U.K.-based Summit Therapeutics said the new ordinary shares sold under the placement were listed on the London Stock Exchange's AIM market and started trading Jan. 9.

Summit Therapeutics is a biopharmaceutical company that focuses on the discovery, development and commercialization of novel medicines to treat rare and infectious diseases.